AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03374618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
Study NCT02112955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke self-management program
Description: A nurse-led community-based self-efficacy enhancing stroke self-management program.
Study NCT02112955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care such as hospital-based or community-based health education or services.
Study NCT02112955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care such as hospital-based or community-based health education or services.
Study NCT03796130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery
Study NCT01432210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-prandial Feeding Study
Study NCT04178356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Training
Description: The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
Study NCT04178356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
Study NCT00760084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
Study NCT03229460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard low flow therapy
Description: In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
Study NCT01769898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 0.1 Q12H
Study NCT03229460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal oxygen therapy
Description: The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
Study NCT01769898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for theophylline 0.1 Q12H
Study NCT03172286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequencer
Description: Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
Study NCT03172286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequencer
Description: Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
Study NCT00454142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT00454142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00454142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies
Study NCT03342859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan, BAY1002670
Description: Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
Study NCT03342859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Daily single oral doses of 5 mg ulipristal over 8-12 weeks
Study NCT02887599 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection
Description: 1ml of blood specimen collection
Study NCT03229460 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: association of high flow nasal oxygen therapy and non invasive positive pressure ventilation
Description: The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
Study NCT02145702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
Study NCT02145702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Care Dialysis
Description: 12 weeks of standard of care.
Study NCT00677430 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A brief questionnaire packet will be completed.
Study NCT00677430 — intervention group
Intervention type: PROCEDURE
Intervention: Digital Imaging
Description: Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
Study NCT03160196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System
Description: It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
Study NCT04531072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir 300/100 mg
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Study NCT00555789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: 200mg oral b.i.d.
Study NCT00521963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of infliximab
Description: A single injection of 100 mg of infliximab
Study NCT01450137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab + Glucocorticoids (GCs)
Description: Tocilizumab 8mg/kg every 4 weeks until week 52.
Study NCT01450137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Glucocorticoids (GCs)
Description: Placebo every 4 weeks until week 52.
Study NCT03580447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus extract
Description: Citrus extract
Study NCT03580447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT03160196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care based on clinical practice guideline
Description: It is about usual care aligned with the diabetes guideline.
Study NCT03231150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Steroid Injection into the plantar heel
Description: Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
Study NCT03231150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Steroid Injection into the plantar heel
Description: Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
Study NCT03231150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Injection
Description: Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
Study NCT03231150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Guided injection
Description: Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
Study NCT00695201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine, Oxaliplatin, CPT-11
Description: For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
Study NCT00695201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine, Oxaliplatin, CPT-11
Description: For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
Study NCT01834859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient program
Description: Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
Study NCT01834859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient lifestyle program
Description: Diet (phase 1) and lifestyle intervention (phase 2)
Study NCT02314143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules.
Study NCT02314143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
Study NCT03420053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
Study NCT03420053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: 0.9% sodium chloride solution
Study NCT04344743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation without contrast
Description: Cryoballoon ablation without contrast
Study NCT00004229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Study NCT01291875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
Study NCT01291875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supragingival biofilm control
Description: Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
Study NCT02383485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Heart rate monitors worn by each child at each session
Study NCT02383485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After-school program
Description: Supervised recreational program with token economy
Study NCT02383485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After-school program
Description: Supervised recreational program with token economy
Study NCT03611465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pace-mapping
Description: Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
Study NCT03611465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard pace-mapping examination
Description: Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
Study NCT00555789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic plus tacrolimus
Description: 720mg b.i.d. 2yrs
Study NCT02764190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT with Check Yourself
Study NCT01233687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 and erlotinib
Description: Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102.
Study NCT00089674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 162
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Study NCT00089674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Study NCT02914145 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dihydroartemisinin-piperaquine
Description: Mass drug administration
Study NCT00652639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Tablets, 1 mg, single-dose
Study NCT03420053 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
Study NCT03420053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
Study NCT00652639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klonopin
Description: tablets, 1 mg, single-dose
Study NCT03095768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Education and Cooking Demonstration
Description: Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
Study NCT00876603 — intervention group
Intervention type: PROCEDURE
Intervention: ACDF
Description: Anterior cervical decompression and fusion
Study NCT00876603 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical laminoplasty
Description: Cervical laminoplasty
Study NCT01706094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head Position
Description: Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients.
Study NCT00617396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg/day-100mg/day)
Description: Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
Study NCT05146076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based physical training
Description: home-based physical training minimum 150 min./week with telemonitoring
Study NCT05146076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: institutional physical training
Description: institutional physical training supervised by physiotherapist 2-3 times 60 min./week
Study NCT00606281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg/day
Study NCT00606281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 0mg(4tablets)/day
Study NCT01710774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine follow-up care
Description: Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
Study NCT03386760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Utilisation PicoSecond
Description: Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions
Study NCT03386760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Utilisation Nano-second
Description: Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions
Study NCT01000376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin alone
Description: Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m\^2 alone on Day 1, then eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
Study NCT01000376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin plus Ketoconazole
Description: Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m\^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
Study NCT05081375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Injectable Product
Description: Not holding prophylaxis dose prior to surgical procedure
Study NCT01851304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of breads
Description: One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
Study NCT05081375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Holding prophylaxis dose of Enoxaparin replacing with placebo
Study NCT03557489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum
Description: Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
Study NCT01851304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Satiety of breads
Description: One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
Study NCT01851304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Satiety of puddings
Description: One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
Study NCT01851304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Satiety of puddings
Description: One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
Study NCT03607136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
Study NCT02347956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced port robotic distal gastrectomy
Study NCT01129284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR gel
Description: Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
Study NCT00894725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic left colonic resection
Description: laparoscopic colonic resection